Conference Track

Addressing Side Effects and Coinfections

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

High-Dose Ribavirin plus Peginterferon With Epoetin Alfa Leads to Higher Sustained Virologic Response for HCV Genotype 1
Initial HAART Curtails Excess Liver Damage in HIV/HCV Coinfection
Tenofovir Suppresses HBV in HIV/HBV-Coinfected Patients Over 4 Years of Treatment in Small, Single-Center Study
APRICOT: Higher Baseline ALT Associated With Higher SVR in HIV/HCV-Coinfected Patients Receiving Peginterferon Plus Ribavirin
Development of Fatigue Reduces 24-Week Virologic Responses to Peginterferon Plus Ribavirin in Chronic Hepatitis C
Lamivudine-Resistant HBV/HIV-Coinfected Patients Respond to Long-Term Adefovir/Lamivudine Therapy With No Adefovir Resistance
24-Weeks of Peginterferon plus Ribavirin Safe and Effective for Acute Hepatitis C in HIV-Positive Patients

Expert Analysis

Addressing Side Effects and Coinfections

Faculty:

Nezam H. Afdhal, MD, FRCPI
Raymond T. Chung, MD
Mark S. Sulkowski, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Review recent studies of approaches to reduce or avoid common side effects of hepatitis treatment
Discuss groups at higher risk for the development of side effects from treatment
Evaluate recent clinical trials of peginterferon and ribavirin for the treatment of hepatitis C virus infection in HIV-infected patients

CME CREDIT INFORMATION

Release Date: 01/27/06

Expiration Date: 01/26/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.